The problem of urogenic and vulval atrophy in menopausal women is typically understood to be a consequence of estrogen deficiency in the respective tissues.
Urogenital atrophy. - PubMed - NCBI
"The major cause of urogenital atrophy in menopausal women is estrogen loss. The symptoms are usually progressive in nature and deteriorate with time from the menopausal transition. The most prevalent urogenital symptoms are vaginal dryness, vaginal irritation and itching. The classical changes in an atrophic vulva include loss of labial and vulvar fullness, with narrowing of the introitus and inflamed mucosal surfaces. Dyspareunia and vaginal bleeding from fragile atrophic skin are common problems."
As such the standard treatment is topical estrogen cream (estriol). One such case is described here (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174723/).
"A 39-year-old female patient was referred from the gynecology department with the complaints of burning and pain sensation during micturition for 3 months...The patient's obstetric history was uneventful. Routine hematological and biochemical investigations were normal. The patient was advised topical estrogen cream for 4 weeks and the lesion resolved completely in 4 weeks".
Prasterone's approval for vulvar and vaginal atrophy is a promising line of treatment.(FDA Approved First Drug Containing DHEA)
Predictably, Prasterone is is understood to exert its therapeutic effects by way of its estrogenicity ( ). Assuming that the androgenic effects of DHEA/Prasterone are significant in terms of its effectiveness...I wonder if the members of this forum might have any thoughts about more explicitly androgenic solutions to this issue? Equally I wonder if anyone had information regarding depletion of estrogen in those tissues as being therapeutic for these issues?
@haidut @Blossom
Urogenital atrophy. - PubMed - NCBI
"The major cause of urogenital atrophy in menopausal women is estrogen loss. The symptoms are usually progressive in nature and deteriorate with time from the menopausal transition. The most prevalent urogenital symptoms are vaginal dryness, vaginal irritation and itching. The classical changes in an atrophic vulva include loss of labial and vulvar fullness, with narrowing of the introitus and inflamed mucosal surfaces. Dyspareunia and vaginal bleeding from fragile atrophic skin are common problems."
As such the standard treatment is topical estrogen cream (estriol). One such case is described here (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174723/).
"A 39-year-old female patient was referred from the gynecology department with the complaints of burning and pain sensation during micturition for 3 months...The patient's obstetric history was uneventful. Routine hematological and biochemical investigations were normal. The patient was advised topical estrogen cream for 4 weeks and the lesion resolved completely in 4 weeks".
Prasterone's approval for vulvar and vaginal atrophy is a promising line of treatment.(FDA Approved First Drug Containing DHEA)
Predictably, Prasterone is is understood to exert its therapeutic effects by way of its estrogenicity ( ). Assuming that the androgenic effects of DHEA/Prasterone are significant in terms of its effectiveness...I wonder if the members of this forum might have any thoughts about more explicitly androgenic solutions to this issue? Equally I wonder if anyone had information regarding depletion of estrogen in those tissues as being therapeutic for these issues?
@haidut @Blossom
Last edited: